DE2722970A1 - Verfahren zur reinigung von praeparaten mit insbesondere interferon- aktivitaet, die gereinigten praeparate und ihre verwendung als arzneimittel - Google Patents
Verfahren zur reinigung von praeparaten mit insbesondere interferon- aktivitaet, die gereinigten praeparate und ihre verwendung als arzneimittelInfo
- Publication number
- DE2722970A1 DE2722970A1 DE19772722970 DE2722970A DE2722970A1 DE 2722970 A1 DE2722970 A1 DE 2722970A1 DE 19772722970 DE19772722970 DE 19772722970 DE 2722970 A DE2722970 A DE 2722970A DE 2722970 A1 DE2722970 A1 DE 2722970A1
- Authority
- DE
- Germany
- Prior art keywords
- interferon
- preparations
- products
- adsorbent
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000014150 Interferons Human genes 0.000 title claims description 89
- 108010050904 Interferons Proteins 0.000 title claims description 89
- 229940079322 interferon Drugs 0.000 title claims description 88
- 238000002360 preparation method Methods 0.000 title claims description 75
- 238000000034 method Methods 0.000 title claims description 37
- 230000000694 effects Effects 0.000 title claims description 36
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000047 product Substances 0.000 claims description 39
- 239000000872 buffer Substances 0.000 claims description 29
- 229920002307 Dextran Polymers 0.000 claims description 24
- 229920002684 Sepharose Polymers 0.000 claims description 24
- 239000003463 adsorbent Substances 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 13
- 150000004676 glycans Chemical class 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229920000936 Agarose Polymers 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000013065 commercial product Substances 0.000 claims description 4
- 238000003795 desorption Methods 0.000 claims description 4
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- -1 agarose Chemical class 0.000 claims description 2
- 230000003328 fibroblastic effect Effects 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 125000003367 polycyclic group Chemical group 0.000 claims description 2
- 150000004804 polysaccharides Polymers 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 17
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
- 238000000746 purification Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000001064 anti-interferon Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229920002972 Acrylic fiber Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7615414A FR2351665A1 (fr) | 1976-05-21 | 1976-05-21 | Procede de purification de preparations possedant notamment une activite interferon, preparations purifiees ainsi obtenues et leur application en tant que medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2722970A1 true DE2722970A1 (de) | 1977-12-08 |
Family
ID=9173478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19772722970 Withdrawn DE2722970A1 (de) | 1976-05-21 | 1977-05-20 | Verfahren zur reinigung von praeparaten mit insbesondere interferon- aktivitaet, die gereinigten praeparate und ihre verwendung als arzneimittel |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4172071A (https=) |
| BE (1) | BE854916A (https=) |
| DE (1) | DE2722970A1 (https=) |
| FI (1) | FI60501C (https=) |
| FR (1) | FR2351665A1 (https=) |
| GB (1) | GB1585601A (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0018218A1 (en) * | 1979-04-20 | 1980-10-29 | Technobiotic Ltd. | Interferon proteins and method of producing same |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410697B1 (en) * | 1979-04-20 | 2002-06-25 | Schering Corporation | Process for purifying human leukocyte interferon |
| JPS5651995A (en) * | 1979-10-05 | 1981-05-09 | Green Cross Corp:The | Preparation of interferon |
| US4278661A (en) * | 1979-10-12 | 1981-07-14 | E. I. Du Pont De Nemours And Company | Purification of interferon |
| US4605394A (en) * | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
| US4362155A (en) * | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
| US4824432A (en) * | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
| JPS5821691A (ja) * | 1981-07-29 | 1983-02-08 | Mochida Pharmaceut Co Ltd | α−及びβ−インタ−フェロンの精製方法 |
| US4499014A (en) * | 1984-02-07 | 1985-02-12 | Interferon Sciences, Inc. | Method for purifying gamma-interferon |
| US4658017A (en) * | 1984-02-14 | 1987-04-14 | Health Research, Inc. (Roswell Park Division) | Method for the large scale purification of human fibroblast interferon |
| US4803163A (en) * | 1984-06-04 | 1989-02-07 | E. I. Du Pont De Nemours And Company | Preparation of a protein fraction exhibiting cell growth-inhibiting activity |
| HU193472B (en) * | 1984-09-21 | 1987-10-28 | Vni Sky I Osobo Chistkykh Biop | Process for purification of human leucocite interferon |
| EP0190606B1 (de) * | 1985-02-04 | 1990-05-09 | F. Hoffmann-La Roche Ag | Adsorbens für die Reinigung von Proteinen |
| US5144013A (en) * | 1986-09-24 | 1992-09-01 | Ube Industries, Ltd. | Body fluid purifying material and method for purifying body fluid by use thereof |
| US5434249A (en) * | 1992-05-27 | 1995-07-18 | Viragen Inc. | Method for modulating specific activity of inteferon alpha |
| US20040199099A1 (en) * | 1998-07-10 | 2004-10-07 | Matson James R | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
| US6287516B1 (en) | 1998-07-10 | 2001-09-11 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
| US7291122B2 (en) * | 2000-03-24 | 2007-11-06 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
| US6736972B1 (en) | 2000-03-24 | 2004-05-18 | Immunocept, L.L.C. | Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases |
| US6787040B2 (en) | 2000-05-16 | 2004-09-07 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
| WO2002074806A2 (en) | 2001-02-27 | 2002-09-26 | Maxygen Aps | New interferon beta-like molecules |
| AU2003255276A1 (en) * | 2002-08-13 | 2004-02-25 | Arbios Systems, Inc. | Selective plasma exchange therapy |
| BR112016013876B1 (pt) * | 2013-12-27 | 2022-03-22 | Eliaz Therapeutics, Inc. | Dispositivo para realização de plasmaferese |
| CN114041622B (zh) * | 2021-10-16 | 2023-06-27 | 深圳市真味生物科技有限公司 | 电子雾化液制备用甜味剂母液脱色的工艺 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB980227A (en) * | 1962-08-16 | 1965-01-13 | Glaxo Lab Ltd | Purification and/or concentration of material containing interferon |
| GB1055895A (en) * | 1963-12-10 | 1967-01-18 | Glaxo Lab Ltd | Interferon purification |
| US3773924A (en) * | 1970-12-24 | 1973-11-20 | M Ho | Interferon production |
| FR2244543B1 (https=) * | 1973-07-27 | 1977-07-01 | Inst Nl Sante Rech Medica | |
| CH600782A5 (https=) * | 1973-09-10 | 1978-06-30 | Research Corp | |
| US4016149A (en) * | 1973-09-10 | 1977-04-05 | Research Corporation | Selective removal of albumin from blood fluid and compositions therefore |
| NL7404589A (nl) * | 1974-04-03 | 1975-10-07 | Stichting Rega V Z W | Werkwijze voor het stabiliseren van interferon. |
| US3975344A (en) * | 1974-10-02 | 1976-08-17 | G. D. Searle & Co. | Interferon purification |
-
1976
- 1976-05-21 FR FR7615414A patent/FR2351665A1/fr active Granted
-
1977
- 1977-05-19 US US05/798,523 patent/US4172071A/en not_active Expired - Lifetime
- 1977-05-20 DE DE19772722970 patent/DE2722970A1/de not_active Withdrawn
- 1977-05-20 FI FI771624A patent/FI60501C/fi not_active IP Right Cessation
- 1977-05-23 GB GB21596/77A patent/GB1585601A/en not_active Expired
- 1977-05-23 BE BE177808A patent/BE854916A/xx not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0018218A1 (en) * | 1979-04-20 | 1980-10-29 | Technobiotic Ltd. | Interferon proteins and method of producing same |
| WO1980002229A1 (en) * | 1979-04-20 | 1980-10-30 | Benzon As Alfred | Interferon proteins and method of producing same |
Also Published As
| Publication number | Publication date |
|---|---|
| FI60501B (fi) | 1981-10-30 |
| FR2351665A1 (fr) | 1977-12-16 |
| FI60501C (fi) | 1983-06-06 |
| GB1585601A (en) | 1981-03-11 |
| FR2351665B1 (https=) | 1978-12-08 |
| FI771624A7 (https=) | 1977-11-22 |
| US4172071A (en) | 1979-10-23 |
| BE854916A (fr) | 1977-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2722970A1 (de) | Verfahren zur reinigung von praeparaten mit insbesondere interferon- aktivitaet, die gereinigten praeparate und ihre verwendung als arzneimittel | |
| DE68915045T2 (de) | Reinigung von Pertussis-Toxinen und Herstellung von Vakzine. | |
| DE3227262C2 (https=) | ||
| DE68922358T2 (de) | Chromatographische Trennung von Plasmaproteinen, insbesondere von Faktor VIII, von Willebrand Faktor, von Fibronectin und von Fibrinogen. | |
| DE3001585C2 (de) | Verfahren zur Herstellung von Interferon Typ I und II | |
| EP1005492B1 (de) | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie | |
| EP0352500A2 (de) | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen immunoglobulin-Präparates mit hohemIgM-Gehalt. | |
| DE69125764T2 (de) | Verfahren zur Herstellung des Von Willebrand-Faktors von höchster Reinheit | |
| CH647158A5 (de) | Verfahren zur reinigung von interferon. | |
| Alender et al. | Isolation and characterization of sea urchin toxin | |
| DE2624815B2 (de) | Herstellung einer injizierbaren, stromafreien und von Plasmaproteinen freien Hämoglobinlösung | |
| DE3019847C2 (de) | Verfahren zur Herstellung von Humaninterferon | |
| DE2718542A1 (de) | Verfahren zur reinigung von interferon | |
| DE2323981C3 (de) | Verfahren zur Isolierung des thrombinartig wirkenden Bestandteils aus dem Gift der Otter Agkistrodon rhodostoma | |
| EP0120835B1 (de) | Verfahren zur Inaktivierung von Unverträglichkeitsreaktionen verursachenden Substanzen | |
| DE3012204A1 (de) | Antigen, verfahren zu seiner herstellung und seine verwendung | |
| DE1940130C2 (de) | Verfahren zur Reinigung von Insulin, nach diesem Verfahren gereinigtes Insulin und dessen Verwendung | |
| CH643861A5 (de) | Verfahren zum reinigen eines gamma-globulinderivats. | |
| EP0873362B1 (de) | VERFAHREN ZUR TRENNUNG VON IgG und IgA | |
| DE2819297A1 (de) | Verfahren zur abtrennung und reinigung von produkten mit interferonaktivitaet, die hierbei erhaltenen produkte und deren verwendung als arzneimittelwirkstoffe | |
| DE1617332B2 (de) | Verfahren zum Isolieren eines wasserlöslichen Protein-Metall-Chelats mit antiphlogistischer Wirkung | |
| DE2828235C2 (de) | Verfahren und Adsorptionsmittel zur Isolierung und Reindarstellung von Enzymen aus einer Roh-Enzym-Lösung | |
| DE2014957C2 (de) | Verfahren zur Reinigung von Proteinen des Blutserums oder -plasmas | |
| DE2420415A1 (de) | Eine mitogenische blutfraktion und verfahren zur herstellung derselben | |
| DE2409650C3 (de) | Verwendung wäßriger Lösung von menschlichem Serum-Haptoglobin bei der Bekämpfung von hämolytischen Nierenstörungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OC | Search report available | ||
| 8141 | Disposal/no request for examination |